azomycin has been researched along with u 100480 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS | 1 |
| Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
| Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
| Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
| Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M | 1 |
| Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G | 1 |
2 review(s) available for azomycin and u 100480
| Article | Year |
|---|---|
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2017 |
4 other study(ies) available for azomycin and u 100480
| Article | Year |
|---|---|
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors | 2012 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis | 2019 |